Histone deacetylase inhibitor for NUT midline carcinoma

Ossama M. Maher; Anthony M. Christensen; Sireesha Yedururi; Diana Bell; Nidale Tarek

doi:10.1002/pbc.25350

Histone deacetylase inhibitor for NUT midline carcinoma

Ossama M. Maher, Anthony M. Christensen, Sireesha Yedururi, Diana Bell, Nidale Tarek

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

NUT Midline carcinoma (NMC) is a rare and invariably fatal poorly differentiated carcinoma characterized by chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene. Current approaches do not provide durable response. We report a case of widely metastatic NMC in a 17-year-old female who, following an initial response to combination chemotherapy developed rapid disease progression. Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis. This report shows a potentially promising activity of HDACi in the treatment of NMC that needs further exploration. Pediatr Blood Cancer 2015;62:715-717.

Original language	English (US)
Pages (from-to)	715-717
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	62
Issue number	4
DOIs	https://doi.org/10.1002/pbc.25350
State	Published - Apr 1 2015

Keywords

Histone deacetylase inhibitor
NUT midline carcinoma

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.25350

Cite this

@article{74b2ecf1a5d24616aa7371ad9301e1a7,

title = "Histone deacetylase inhibitor for NUT midline carcinoma",

abstract = "NUT Midline carcinoma (NMC) is a rare and invariably fatal poorly differentiated carcinoma characterized by chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene. Current approaches do not provide durable response. We report a case of widely metastatic NMC in a 17-year-old female who, following an initial response to combination chemotherapy developed rapid disease progression. Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis. This report shows a potentially promising activity of HDACi in the treatment of NMC that needs further exploration. Pediatr Blood Cancer 2015;62:715-717.",

keywords = "Histone deacetylase inhibitor, NUT midline carcinoma",

author = "Maher, {Ossama M.} and Christensen, {Anthony M.} and Sireesha Yedururi and Diana Bell and Nidale Tarek",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2015",

month = apr,

day = "1",

doi = "10.1002/pbc.25350",

language = "English (US)",

volume = "62",

pages = "715--717",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Histone deacetylase inhibitor for NUT midline carcinoma

AU - Maher, Ossama M.

AU - Christensen, Anthony M.

AU - Yedururi, Sireesha

AU - Bell, Diana

AU - Tarek, Nidale

PY - 2015/4/1

Y1 - 2015/4/1

N2 - NUT Midline carcinoma (NMC) is a rare and invariably fatal poorly differentiated carcinoma characterized by chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene. Current approaches do not provide durable response. We report a case of widely metastatic NMC in a 17-year-old female who, following an initial response to combination chemotherapy developed rapid disease progression. Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis. This report shows a potentially promising activity of HDACi in the treatment of NMC that needs further exploration. Pediatr Blood Cancer 2015;62:715-717.

AB - NUT Midline carcinoma (NMC) is a rare and invariably fatal poorly differentiated carcinoma characterized by chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene. Current approaches do not provide durable response. We report a case of widely metastatic NMC in a 17-year-old female who, following an initial response to combination chemotherapy developed rapid disease progression. Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis. This report shows a potentially promising activity of HDACi in the treatment of NMC that needs further exploration. Pediatr Blood Cancer 2015;62:715-717.

KW - Histone deacetylase inhibitor

KW - NUT midline carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84923170142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923170142&partnerID=8YFLogxK

U2 - 10.1002/pbc.25350

DO - 10.1002/pbc.25350

M3 - Article

C2 - 25557064

AN - SCOPUS:84923170142

SN - 1545-5009

VL - 62

SP - 715

EP - 717

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Histone deacetylase inhibitor for NUT midline carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this